Pila Pharma

Pila Pharma is a Malmö-based biotech company developing XEN-D0501, a first-in-class oral TRPV1 inhibitor for the treatment of obesity and type 2 diabetes. Unlike injectable GLP-1 drugs like Ozempic, XEN-D0501 is a tablet-based treatment with a distinct mechanism targeting the TRPV1 receptor — a key regulator of pain, temperature, and metabolism. Founded by former Novo Nordisk researcher Dr. Dorte X. Gram, the company raised SEK 30M in an oversubscribed 293% share issue in October 2025 and is listed on Nasdaq First North.